Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

Summary

The bill changes New York law so that for drugs such as mifepristone, misoprostol, GnRH agonists, pubertal suppressants, anabolic steroids, alpha‑reductase inhibitors, progestins, and hormone‑replacement therapy used for gender dysphoria, the label can show the clinic’s name or address rather than the specific prescriber or pharmacist. Prescribers must inform patients when this substitution is made. The amendment takes effect immediately.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share